Skip to main content

Recherche

Reset all filters
230 Result(s)
Trier par

Our Approach

Our Approach

We are driven by the desire to improve human and animal health -– now and in the future. Therefore, we have developed our framework: Sustainable Development – For Generations.
Notre contribution

Notre contribution

Humanity is facing serious challenges. We believe we can always do more – for ourselves and for the generations to come.
Notre culture du partenariat

Notre culture du partenariat

We embrace the power of partnerships and alliances to find even more breakthrough therapies that change lives.
Notre engagement

Notre engagement

We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals.
WeBuy

WeBuy

Une société prospère et indépendante
Publication EFPIA

Publication EFPIA

Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations and disclosures of transfers of value (ToVs) to HCPs and HCOs.
Media Overview

Media Overview

Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
VAXXITEK HVT + IBD

VAXXITEK HVT + IBD

To prevent mortality and to reduce clinical signs and lesions of infectious bursal disease. To reduce mortality, clinical signs and lesions of Marek’s disease.